LONDON — Back when Jack O’Meara and Quin Wills were initially setting up Ochre Bio, they jumped from their home base in the UK to the US primarily so they could establish a syndicate of investors who could fund their startup as they began to explore new RNA therapies for liver diseases.
And the strategy is working fine.
Along the way, they got to know a lot of the people at Y Combinator, setting up a $10 million seed round last year that put them on track to the $30 million launch round the CEO/CSO founder team is unveiling today. Their backers now include Intellia founder Nessan Bermingham at Khosla as well as Alice Zhang, the CEO at Verge Genomics who is putting some of her own money behind Ochre.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,700+ biopharma pros reading Endpoints daily — and it's free.
"gather" - Google News
October 10, 2022 at 10:56AM
https://ift.tt/nybIkJA
BIO chief McMurry-Heath on leave as storm clouds gather over group's direction, legislative setback - Endpoints News
"gather" - Google News
https://ift.tt/Vdg5I3n
https://ift.tt/ESIkg5O
Bagikan Berita Ini
0 Response to "BIO chief McMurry-Heath on leave as storm clouds gather over group's direction, legislative setback - Endpoints News"
Post a Comment